4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: Syntheses, chemical and pharmacological properties

European Journal of Medicinal Chemistry

Volumn 39, Issue 12, 2004, Pages 1001-1011

  Albuschat, Rica ^a   Löwe, Werner ^a   Weber, Manuela ^a   Luger, Peter ^a   Jendrossek, Verena ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

4 Anilinoquinazolines; Antiproliferative effects; EGFR tyrosine kinase inhibitory activity; Inclusion of solvents; Quinones; Salicylanilides

Indexed keywords

2 [[4 (3 BROMOPHENYLAMINO)QUINAZOLIN 6 YLAMINO]METHYL]BENZENE 1,4 DIOL; 2 [[4 (3 CHLORO 4 FLUOROPHENYLAMINO)QUINAZOLIN 6 YLAMINO]METHYL]BENZENE 1,4 DIOL; CANERTINIB; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; HYDROGEN; HYDROQUINONE DERIVATIVE; LAVENDUSTIN A; N,N DIMETHYLFORMAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINONE DERIVATIVE; SOLVENT; UNCLASSIFIED DRUG; WATER;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; INHIBITION KINETICS; KIDNEY CANCER; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; OVARY CANCER; OXIDATION; X RAY ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROQUINONES; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHENOLS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 9644259011     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmech.2004.03.010     Document Type: Article

References (40)

1. Aaronson S.A. Science 254 1991 1146 1152
2. Yarden Y., and Sliwkowski M.X. Nat. Rev. Mol. Cell Biol. 2 2001 127
3. Salomon D., and Gullick W. Signal J. 2 3 2001 4 11
4. Pederson M.W., and Poulson H.S. Sci. Med. 2002 32 43
5. Raymond E., Faivre S., and Armand J.P. Drugs 60 1 2000 15 23
6. Levitzki A., and Gazit A. Science 267 1995 1782 1788
7. Arteaga C.L. J. Clin. Oncol. 19 15 2001 32S 40S
8. Ciardiello F., Caputo R., Bianco R., Vincenzo D., Somatico G., De Placido S., Bianco R.A., and Tortora G. Clin. Cancer Res. 6 2000 2053 2063
9. Pollack V., Savage D.M., and Baker D.A. J. Pharmacol. Exp. Ther. 291 2 1999 739 748
10. Albuschat R. Doctoral Thesis 2003 Free University of Berlin 90 93
11. Onoda T., Iinuma H., Sasaki Y., Hamada M., Isshiki K., Naganawa H., and Takeuchi T.J. J. Nat. Prod. 42 6 1989 1252 1257
12. Hodge C.N., and Pierce J.A. Bioorg. Med. Chem. Lett 3 1993 1605 1608
13. Traxler P., Green J., Mett H., Sequin U., and Furet P. J. Med. Chem. 42 6 1999 1018 1026
14. Rewcastle G.W. J. Med. Chem. 38 18 1995 3482 3487
15. Baselga J., and Averbruch S.D. Drugs 60 1 2000 33 40
16. Sherwood V., Bridges A.J., Denny W.A., Rewcastle G.W., Smaill J.B., and Fry D.W. Proc. Am. Assoc. Cancer Res. 41 2000 3076
17. Smaill J.B. J. Med. Chem. 42 10 1999 1803 1815
18. Morin M.J. Oncogene 19 2000 6574 6583
19. Vincent P.W., Patmore S.J., Atkinson B.E., Bridges A.J., Kirkish L.S., Dudeck R.C., Leopold W.R., Zhou H., and Elliott W.L. Proc. Am. Assoc. Cancer Res. 40 1999 117
20. Fry D.W., Bridges A.J., Doherty A., Greis K., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., and Dobrusin E. Proc. Natl. Acad. Sci. USA 95 1998 12022 12027
21. Tsou H.R. J. Med. Chem. 44 3 2001 2719 2734
22. Billmann J.H., and McDowell J.W. J. Org. Chem. 26 1961 1437 1440
23. Keller E. SCHAKAL 88:A Fortran Program for the Graphical Representation of Molecular and Crystallographic Models 1988 University of Freiburg, Germany
24. Grever M.R., and Schepartz B.A. Life Sci. 57 1995 131 141
25. Boyd M.R., and Paul K.D. Drug Dev. Res. 34 1995 91
26. Hong W.K., and Ullrich A. Oncol Biother. 1 1 2000 2 6
27. Sawyers C.L. N. Engl. J. Med. 340 1999 1330 1340
28. Buchdunger E., Zimmermann J., and Mett H. Cancer Res. 56 1996 100 104
29. Glivec N.N. Summary of Product Characteristics Novartis Pharma AG 2001 (imatinib)
30. Carroll M., Ohno-Jones S., and Tamura S. Blood 90 1997 4947 4952
31. Altomare A., Cascarono G., Giacovazzo C., Guagliardi A., Burla M.C., Polidori G., and Camalli M. J. Appl. Crystallogr. 27 1994 435
32. Sheldrick G.M. SHELXL-97 A Program for Refinement of Crystal Structures Technical Report 1997 University of Göttingen, Germany
33. Bruker SMART SAINT-Plus and SADABS Data Collection and Processing Software for the SMART System 2002 Bruker AXS Madison, Wisconsin, USA
34. Geissler J.F., Traxler P., Regenass U., Murray B.J., Roesel J.L., Meyer T., McGlynn E., Storni A., and Lydon N.B. J. Biol. Chem. 265 1990 22255 22261
35. Wedegartner P.S., and Gill G.N. J. Biol. Chem. 264 1989 11346 11353
36. Yaish P., Gazit A., Golin C., and Levitzki A. Science 242 1988 933 935
37. A. Lin, MDS Pharma Services, Taiwan, R.O.C., correspondence.
38. Jendrossek V., Erdlenbruch B., Hunold H., Kugler W., Eibl H., and Lakomek M. Intern. J. Oncol. 14 1999 15 22
39. Alley M.C., Scudiero D.A., Monks P.A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., and Boyd M.R. Cancer Res. 48 1988 589 601
40. Grever M.R., Schepartz S.A., and Chabner B.A. Sem. Oncol. 19 6 1992 622 638